Fusion Antibodies have developed a next generation computer platform for rapid, high quality generation of humanized antibodies.

The CDRx platform modernizes the traditional CDR grafting technique by in silico grafting parental CDR’s into mature human antibody frameworks. The CDRx platform screens a database of over 100,000 antibody sequences with bespoke algorithms and, by multiple analytical techniques, defines a panel of human donor frameworks. Once generated, the full length humanized antibodies can be further refined (or germlined) to be even more “human”.

The CDRx platform has went from strength to strength over the past 12 months and thanks to our two-fold affinity guarantee we have seen a 100% success rate. Moreover, we have had the privilege to work with some fantastic clients and humanize what promises to be crucially important drugs in their respective fields. Following recent announcement of the CALY-002 humanization with Calypso Biotech for Celiac Disease, Fusion Antibodies plan to soon announce a new collaboration for humanization of a anti-fungal antibody. This proves the versatility of our platform and the range of exciting targets we can humanize in addition to those in the oncology field.

Fusion Antibodies CDRx platform allows rapid antibody humanization in as little as 12 weeks

The Fusion Antibodies Humanization CDRx platform allows us to do more than our competitors because we not only have no theoretical limit to the number of sequences we can analyse, but we can do complex analysis extremely fast. We can deliver a panel humanized sequences in as little as two weeks, with gene synthesis and transient expression of proof-of-concept material in as little as 12 weeks. We screen for t-cell epitopes, produce a chimeric control antibody in parallel and most importantly don’t charge any royalties. Our modular ordering system allows our clients to pick and choose the services they require allowing for maximum flexability.

The next 12 months looks set to be very exciting as we develop the platform further and see progression of our clients humanized antibodies through the clinic.

Andrew Glover, Business Development Executive

Our Fsn0503 poster will be displayed at this year’s International Conference on Molecular Targets and Cancer Therapeutics

Our poster for “Fsn0503h antibody-mediated blockade of cathepsin S as potential therapeutic strategy for the treatment of solid tumors.” Will be displayed at:

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics


October 19-23, 2013
Hynes Convention Center
Boston, MA, USA  Fsn0503h antibody-mediated blockade of cathepsin S as potential therapeutic strategy for the treatment of solid tumors .

Session ID: Poster Session C

Session Title: Monoclonal Antibodies

Session Date and Time: Tuesday Oct 22, 2013 12:30 PM – 7:30

PMLocation: Exhibit Hall C-D

Permanent Abstract Number: C161

Fusion Antibodies Ltd have today announced a collaboration with Swiss biotech company Calypso Biotech for development of their CALY-002 Antibody.

Belfast UK and Geneva Switzerland22nd July 2013 – Fusion Antibodies Ltd have today announced a collaboration with Swiss biotech company Calypso Biotech for development of their CALY-002 Antibody. The humanization program CALY-002 partnered with Fusion Antibodies relates to the in-licensing by Calypso Biotech of a monoclonal antibody from iDD Biotech, to be developed for treating Refractory Celiac Disease, a rare and devastating form of immune response to gluten.

Fusion Antibodies collaboration with Calypso biotech is the latest in a series of successful Humanization projects. « We are delighted to be working with Calypso Biotech on such an exciting project and are enthusiastic to apply the Fusion Antibodies CDRx Humanization Platform to Calypso’s lead antibody and rapidly advance a high quality humanized antibody towards the clinic » says Paul Kerr, Managing Director of Fusion Antibodies.

Calypso Biotech SA is a spin-off company from Merck Serono, a division of Merck, Darmstadt, Germany, incorporated in March 2013 in Switzerland. Calypso Biotech discovers and develops antibodies for the treatment of gastrointestinal autoimmune diseases. « We are very confident that Fusion Antibodies will provide a high-quality humanized candidate in a time and resource-efficient manner for our CALY-002 program » says Alain Vicari, co-founder of Calypso Biotech.

The project is expected to progress over the summer with early results expected in the coming months.

About Fusion Antibodies

Fusion Antibodies; a UK based life science company, with innovative technologies and world-class expert services for antibody drug discovery, are specialists in production of High Quality Humanized Monoclonal Antibodies and Antibody Engineering Projects. With experience building since 2001 in the medical research industry, including two Antibodies in clinical and pre-clinical trials, Fusion Antibodies have extensive experience in accelerating therapeutic drug research towards the clinic.

Fusion Antibodies has the knowledge and expertise to build and deliver a bespoke package of the services you need to achieve outstanding results. They provide  Royalty  Free  Antibody  Humanization  of  Monoclonal Antibodies and using  their next  generation  in  silico  CDRx™  technology,  they  have  modernized the  traditional  CDR  grafting  technique. Fully humanized  monoclonal  antibodies  are  an  essential  step  in  the  progression  of  therapeutic drugs to the clinic and the in-house expertise at Fusion Antibodies ensures its success.

Visit their website at www.fusionantibodies.com to find our more

Here are some of the events Fusion Antibodies will be attending in 2013

Happy New Year Everyone!

Here are some of the events Fusion Antibodies will be attending in 2013:

BioEurope Spring 2013 – http://www.ebdgroup.com/bes/ – March 11th – 13th 2013 – Barcelona

Bio 2013 – http://convention.bio.org/ – April 22nd -25th 2013 – Chicago

Anglonordic Biotech Conference – http://www.anglonordicbiotech.com/ – June 13th 2013 – London

We look forward to meeting you all again at these conferences!

Fusion Antibodies are proud to offer a new and unique service of generation of antibodies which are hybrids of two of your Therapeutic monoclonals.

With the recent press attention surrounding the first FDA approved bi-specific antibody; catumaxomab and the announcement of the Humanization of Fusion Therapeutics very own fsn1006 double-targeting antibody, there has never been a better time to combine the effects of your antibodies.

Fusion Antibodies have a long history of custom scFv and Fab fragment production and we are excited to offer this great new service to you.

For more details on Bi-Specific Antibody Production and for pricing please contact us today at info@fusionantibodies.com or call us on +44(0) 28 9043 2800

Fusion Antibodies will be attending this years European Cancer Cluster conference on November 11th in Hamburg, Germany.

Update: Fusion Antibodies will now be presenting our recent announcement of the humanization of the double EGF targeting fsn1006 antibody at ECC 2012!

Fusion Antibodies will be attending this years European Cancer Cluster conference on November 11th in Hamburg, Germany.

If you would like to meet us there you can arrange a one-to-one meeting at http://www.ecc-partnering.com/ or contact us by email at info@fusionantibodies.com.

This years conference looks like its going to the best yet, see you there!

Fusion Antibodies have the knowledge and expertise to take your project from ANY stage and produce a fully humanized monoclonal antibody ready for cGMP scale up.

Whether you have a murine monoclonal antibody, an antibody sequence, a recombinant protein or even an ascension number for an interesting target, Fusion Antibodies can work with you to develop a humanized antibody.

We have many years experience in the therapeutic drug industry and have produced hundreds of monoclonal antibodies and thousands of recombinant proteins. We specialise in custom antibody construction such as scFv and Fab fragments, transient protein expression in mammalian and bacterial systems and development of stable cell lines. We have partnerships with many world class companies for cGMP level production, biacore antibody analysis and protein sequencing. Our highly skilled team has the knowledge and experience to guide and advise you through every step of your antibody engineering project and we are confident that you will happy with the results.

We are so confident with our antibody DNA sequencing services that we even guarantee its results. If we don’t get an antibody sequence, you don’t pay a penny. Whats more, all of our antibody engineering and humanization services are 100% royalty free, an industry first which allows you you to keep more of your long term profits.

Why not see what Fusion Antibodies can do for your research projects today and contact us for a no-obligation discussion about how we can accelerate your research towards the clinic.

Fusion Antibodies will be attending HAH 2012 and Bioeurope 2012. We look forward to seeing you there!

Human Antibodies and Hybridomas Conference 2012

Dr Richard Buick will be speaking at this years Human Antibodies & Hybridomas conference in Orlando, Florida. The conference will include lectures, papers and posters surrounding key aspects of human antibody and hybridoma technology, applications and engineering.

For more details on the conference please visit this website or to arrange a meeting contact us at info@fusionantibodies.com or +44 (0)28 9043 2800

BioEurope 2012

Dr Paul Kerr will also be attending Bio Europe 2012, November 12–14, 2012 in Hamburg, Germany. This conference offers great partnering opportunities for European biotechnology companies as well as a range of great presentations for a variety of mid-size and big pharmaceutical companies.

To arrange a one-to-one meeting, visit the BioEurope Partnering Page or contact us by email at info@fusionantibodies.com or call +44 (0)28 9043 2800.

Fusion Antibodies will be speaking at this years Contract Manufacturing Summit 2012.

The conference takes place from 2nd-3rd October in London, UK at the Hilton Olympia Hotel.

This years conference looks set to cover some great topics including; relationship development and management, business models and strategies for the CMO industry and the major challenges of contract manufacturing projects.

For more details on the conference please visit their website or to arrange a meeting contact Dr. Paul Kerr at info@fusionantibodies.com or +44 (0)28 9043 2800

Whatever stage your research project is at, whatever your current expression/purity levels are we want to improve them!

Here at Fusion Antibodies we always want the best. We want higher protein expression levels, higher purity, more stability and lower expression and purification time-scales. Through many years of contract research Fusion Antibodies have developed the expertise to be the best and we want you to challenge that!

Fusion Antibodies offer both bacterial and mammalian expression services alongside a range of protein purification technologies developed by our team of world-class scientists. Whatever stage your research project is at, whatever your current expression/purity levels are we want to improve them!

So check out our Recombinant Protein Expression Services pages, or Contact us today at info@fusionantibodies.com for a no-obligation discussion about the future of your research.